Thursday, March 24, 2016

mPEG-PLGA nanoparticles investigated as part of dual-drug chemotherapeutic treatment of brain cancer

PolySciTech division of Akina, Inc. ( provides a wide array of research products including biodegradable block copolymer mPEG-PLGA. Recently, this polymer was used for generating nanoparticles loaded with two chemotherapeutic drugs. These include paclitaxel, an anti-mitotic drug derived from the Pacific yew tree commonly used in treatment of cancer, and Temozolomide, a drug which acts to damage DNA of tumor cells making it unreadable and triggering cell-death.  The co-delivery of these chemotherapeutic agents in a nanoparticle system was found to significantly reduce brain tumor cell growth and proliferation in mice. Read more: Xu, Y., M. Shen, Y. Li, Y. Sun, Y. Teng, Y. Wang, and Y. Duan. "The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells." Oncotarget (2016).

“Abstract: To get better chemotherapy efficacy, the optimal synergic effect of Paclitaxel (PTX) and Temozolomide (TMZ) on glioblastoma cells lines was investigated. A dual drug-loaded delivery system based on mPEG-PLGA nanoparticles (NPs) was developed to potentiate chemotherapy efficacy for glioblastoma. PTX/TMZ-NPs were prepared with double emulsification solvent evaporation method and exhibited a relatively uniform diameter of 206.3 ± 14.7 nm. The NPs showed sustained release character. Cytotoxicity assays showed the best synergistic effects were achieved when the weight ratios of PTX to TMZ were 1:5 and 1:100 on U87 and C6 cells, respectively. PTX/TMZ-NPs showed better inhibition effect to U87 and C6 cells than single drug NPs or free drugs mixture. PTX/TMZ-NPs (PTX: TMZ was 1:5(w/w)) significantly inhibited the tumor growth in the subcutaneous U87 mice model. These results indicate that coordinate administration of PTX and TMZ combined with NPs is an efficient method for glioblastoma.”
Post a Comment